Spots Global Cancer Trial Database for lomustine
Every month we try and update this database with for lomustine cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| Radiation Therapy With and Without Combination Chemotherapy in Patients With Resected Anaplastic Oligodendroglioma | NCT00002840 | Brain and Centr... | lomustine procarbazine hy... vincristine sul... radiation thera... | 16 Years - 69 Years | European Organisation for Research and Treatment of Cancer - EORTC | |
| Efficacy and Safety of AP 12009 in Patients With Recurrent or Refractory Anaplastic Astrocytoma or Secondary Glioblastoma | NCT00761280 | Anaplastic Astr... Glioblastoma | trabedersen temozolomide Drug delivery s... Placement of Dr... carmustine lomustine | 18 Years - 70 Years | Isarna Therapeutics GmbH | |
| A Dose-Escalation Study in Participants With Recurrent Malignant Glioma | NCT01682187 | Glioma | LY2157299 Lomustine | 18 Years - | Eli Lilly and Company | |
| Bevacizumab and Lomustine for Recurrent GBM | NCT01290939 | Glioblastoma Mu... Cognition Disor... Disability Eval... | bevacizumab lomustine DNA methylation... laboratory biom... cognitive asses... quality-of-life... | 18 Years - | European Organisation for Research and Treatment of Cancer - EORTC | |
| Enzastaurin Versus Lomustine in Glioblastoma | NCT00295815 | Glioblastoma | enzastaurin lomustine | 18 Years - | Eli Lilly and Company | |
| Standard Dose Bevacizumab Versus Low Dose Bevacizumab Plus Lomustine (CCNU) for Recurrent Glioblastoma Multiforme (GBM) | NCT01067469 | Brain Cancer Glioblastoma | Standard Dose B... Low Dose Bevaci... Lomustine | 18 Years - | M.D. Anderson Cancer Center | |
| Bevacizumab and Lomustine for Recurrent GBM | NCT01290939 | Glioblastoma Mu... Cognition Disor... Disability Eval... | bevacizumab lomustine DNA methylation... laboratory biom... cognitive asses... quality-of-life... | 18 Years - | European Organisation for Research and Treatment of Cancer - EORTC | |
| Regorafenib in Relapsed Glioblastoma | NCT02926222 | Glioblastoma Mu... | Regorafenib Lomustine | 18 Years - | Istituto Oncologico Veneto IRCCS | |
| Combination Chemotherapy in Treating Children With Progressive Brain Tumors | NCT00002944 | Brain Tumors Central Nervous... | carboplatin lomustine procarbazine hy... thioguanine vincristine sul... | - 9 Years | Children's Oncology Group | |
| A Study of Selinexor in Combination With Standard of Care Therapy for Newly Diagnosed or Recurrent Glioblastoma | NCT04421378 | Glioblastoma Mu... | Selinexor Temozolomide (T... Lomustine (CCNU... Standard Fracti... Bevacizumab TTField Carmustine | 18 Years - | Karyopharm Therapeutics Inc | |
| Anti-Lag-3 (Relatlinib) and Anti-PD-1 Blockade (Nivolumab) Versus Standard of Care (Lomustine) for the Treatment of Patients With Recurrent Glioblastoma | NCT06325683 | Recurrent Gliob... | Biopsy Biospecimen Col... Lomustine Magnetic Resona... Nivolumab Relatlimab Surgical Proced... | 18 Years - | National Cancer Institute (NCI) | |
| Combination Chemotherapy and Bone Marrow Transplantation or Peripheral Stem Cell Transplantation in Treating Patients With Oligodendroglioma | NCT00003101 | Brain and Centr... | filgrastim busulfan lomustine procarbazine hy... thiotepa vincristine sul... autologous bone... peripheral bloo... | 18 Years - | Memorial Sloan Kettering Cancer Center | |
| Radiation Therapy and Combination Chemotherapy in Treating Young Patients With Metastatic Medulloblastoma Who Have Undergone Surgery | NCT00276666 | Brain and Centr... | cisplatin lomustine vincristine sul... adjuvant therap... radiation thera... | 3 Years - 21 Years | National Cancer Institute (NCI) | |
| Chemotherapy, Filgrastim, and Radiation Therapy in Treating Patients With Primary Central Nervous System Lymphoma | NCT00003929 | Lymphoma | filgrastim lomustine procarbazine hy... radiation thera... | - | Case Comprehensive Cancer Center | |
| Ph 1/2 CTO With Lomustine for Bevacizumab-Naive Recurrent Glioma | NCT01989052 | Malignant Gliom... | CTO Lomustine | 18 Years - | Duke University | |
| Lomustine in Treating Patients With Stage III or Stage IV Non-Small Cell Lung Cancer | NCT00293280 | Lung Cancer | lomustine | 18 Years - | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | |
| Inducing a Hypothyroxinemic State in Patients With Recurrent Glioblastoma or Gliosarcoma | NCT05017610 | Recurrent Gliob... Recurrent Glios... | Liothyronine Lomustine Methimazole | 18 Years - | Emory University | |
| Phase Ib/II Study of Buparlisib Plus Carboplatin or Lomustine in Patients With Recurrent Glioblastoma Multiforme | NCT01934361 | Recurrent Gliob... | buparlisib carboplatin lomustine placebo | 18 Years - | Novartis | |
| Bevacizumab and Lomustine for Recurrent GBM | NCT01290939 | Glioblastoma Mu... Cognition Disor... Disability Eval... | bevacizumab lomustine DNA methylation... laboratory biom... cognitive asses... quality-of-life... | 18 Years - | European Organisation for Research and Treatment of Cancer - EORTC | |
| A Study of Treatment for Medulloblastoma Using Sodium Thiosulfate to Reduce Hearing Loss | NCT05382338 | Medulloblastoma | Cisplatin Cyclophosphamid... Lomustine Mesna Quality-of-Life... Radiation Thera... Sodium Thiosulf... Survey Administ... Vincristine | 3 Years - 21 Years | Children's Oncology Group | |
| Low-Dose Radiation and Combination Chemotherapy Following Surgery in Children With Newly Diagnosed Medulloblastoma | NCT00031590 | Brain Tumors Central Nervous... Medulloblastoma | Cisplatin Cyclophosphamid... Etoposide Lomustine Vincristine Craniospinal Ra... | 3 Years - 30 Years | Children's Hospital of Philadelphia | |
| Adult Study: ABT-414 Alone or ABT-414 Plus Temozolomide vs. Lomustine or Temozolomide for Recurrent Glioblastoma Pediatric Study: Evaluation of ABT-414 in Children With High Grade Gliomas | NCT02343406 | Glioblastoma | Depatuxizumab m... Temozolomide Lomustine | - 99 Years | AbbVie | |
| A Trial to Evaluate Multiple Regimens in Newly Diagnosed and Recurrent Glioblastoma | NCT03970447 | Glioblastoma | Temozolomide Lomustine Regorafenib Radiation Paxalisib VAL-083 VT1021 Troriluzole ADI-PEG 20 | 18 Years - | Global Coalition for Adaptive Research | |
| A Study of Treatment for Medulloblastoma Using Sodium Thiosulfate to Reduce Hearing Loss | NCT05382338 | Medulloblastoma | Cisplatin Cyclophosphamid... Lomustine Mesna Quality-of-Life... Radiation Thera... Sodium Thiosulf... Survey Administ... Vincristine | 3 Years - 21 Years | Children's Oncology Group | |
| Combination Chemotherapy and Radiation Therapy With or Without Methotrexate in Treating Young Patients With Newly Diagnosed Gliomas | NCT00278278 | Brain and Centr... | cisplatin etoposide ifosfamide lomustine methotrexate prednisone vincristine sul... | 3 Years - 18 Years | National Cancer Institute (NCI) | |
| Lomustine in Treating Patients With Stage III or Stage IV Non-Small Cell Lung Cancer | NCT00293280 | Lung Cancer | lomustine | 18 Years - | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | |
| Investigator-Initiated Study of Imipramine Hydrochloride and Lomustine in Recurrent Glioblastoma | NCT04863950 | Glioblastoma | Lomustine Imipramine Hydr... | - | The University of Texas Health Science Center at San Antonio | |
| Sonocloud-9 in Association With Carboplatin Versus Standard-of-Care Chemotherapies (CCNU or TMZ) in Recurrent GBM | NCT05902169 | Glioblastoma Recurrent Gliob... GBM | SonoCloud-9 (SC... Carboplatin Lomustine Temozolomide | 18 Years - | CarThera | |
| Adult Study: ABT-414 Alone or ABT-414 Plus Temozolomide vs. Lomustine or Temozolomide for Recurrent Glioblastoma Pediatric Study: Evaluation of ABT-414 in Children With High Grade Gliomas | NCT02343406 | Glioblastoma | Depatuxizumab m... Temozolomide Lomustine | - 99 Years | AbbVie | |
| Chemotherapy, Filgrastim, and Radiation Therapy in Treating Patients With Primary Central Nervous System Lymphoma | NCT00003929 | Lymphoma | filgrastim lomustine procarbazine hy... radiation thera... | - | Case Comprehensive Cancer Center | |
| Radiation Therapy Followed By Combination Chemotherapy in Treating Young Patients With Supratentorial Primitive Neuroectodermal Tumors | NCT00274911 | Brain and Centr... | cisplatin lomustine vincristine sul... adjuvant therap... radiation thera... | 3 Years - 18 Years | National Cancer Institute (NCI) | |
| Temozolomide Plus Lomustine Followed by Radiation Therapy in Treating Patients With High-Grade Malignant Glioma | NCT00006024 | Brain Tumor Central Nervous... | lomustine temozolomide | 3 Years - 21 Years | Children's Oncology Group | |
| Observation or Radiation Therapy With or Without Combination Chemotherapy in Treating Patients With Low-Grade Glioma | NCT00003375 | Brain and Centr... | lomustine procarbazine hy... vincristine sul... radiation thera... | 18 Years - 120 Years | Radiation Therapy Oncology Group | |
| Lomustine and Intermediate Dose Cytarabine in Older Patients With AML | NCT00480064 | Acute Myeloid L... | Lomustine, inte... | 60 Years - | French Innovative Leukemia Organisation | |
| Regorafenib in Relapsed Glioblastoma | NCT02926222 | Glioblastoma Mu... | Regorafenib Lomustine | 18 Years - | Istituto Oncologico Veneto IRCCS | |
| Phase Ib/II Study of Buparlisib Plus Carboplatin or Lomustine in Patients With Recurrent Glioblastoma Multiforme | NCT01934361 | Recurrent Gliob... | buparlisib carboplatin lomustine placebo | 18 Years - | Novartis | |
| A Comparison of Continuous Bevacizumab (Avastin) Treatment or Placebo in Addition to Lomustine Followed by Standard of Care After Disease Progression in Participants With Glioblastoma | NCT01860638 | Glioblastoma | Bevacizumab Lomustine Placebo Radiotherapy Temozolomide SOC Agent | 18 Years - | Hoffmann-La Roche | |
| Regorafenib in Relapsed Glioblastoma | NCT02926222 | Glioblastoma Mu... | Regorafenib Lomustine | 18 Years - | Istituto Oncologico Veneto IRCCS | |
| A Study in Recurrent Glioblastoma (GB) | NCT01582269 | Glioblastoma | LY2157299 monoh... Lomustine Placebo | 18 Years - | Eli Lilly and Company | |
| Combination Chemotherapy Followed By Stem Cell Transplant in Treating Young Patients With Progressive or Relapsed Anaplastic Large Cell Lymphoma | NCT00317408 | Lymphoma | anti-thymocyte ... busulfan carboplatin carmustine cyclosporine cytarabine dexamethasone etoposide phosp... idarubicin ifosfamide leucovorin calc... lomustine melphalan methotrexate mitoxantrone hy... prednisolone thiotepa vinblastine sul... vindesine allogeneic hema... autologous hema... peripheral bloo... total-body irra... | - 21 Years | National Cancer Institute (NCI) | |
| Combination Chemotherapy Followed By Stem Cell Transplant in Treating Young Patients With Progressive or Relapsed Anaplastic Large Cell Lymphoma | NCT00317408 | Lymphoma | anti-thymocyte ... busulfan carboplatin carmustine cyclosporine cytarabine dexamethasone etoposide phosp... idarubicin ifosfamide leucovorin calc... lomustine melphalan methotrexate mitoxantrone hy... prednisolone thiotepa vinblastine sul... vindesine allogeneic hema... autologous hema... peripheral bloo... total-body irra... | - 21 Years | National Cancer Institute (NCI) | |
| Combination Chemotherapy in Treating Children With Progressive Brain Tumors | NCT00002944 | Brain Tumors Central Nervous... | carboplatin lomustine procarbazine hy... thioguanine vincristine sul... | - 9 Years | Children's Oncology Group | |
| Low-Dose Radiation and Combination Chemotherapy Following Surgery in Children With Newly Diagnosed Medulloblastoma | NCT00031590 | Brain Tumors Central Nervous... Medulloblastoma | Cisplatin Cyclophosphamid... Etoposide Lomustine Vincristine Craniospinal Ra... | 3 Years - 30 Years | Children's Hospital of Philadelphia | |
| Intrathecal Radioimmunotherapy, Radiation Therapy, and Chemotherapy After Surgery in Treating Patients With Medulloblastoma | NCT00058370 | Brain and Centr... | cisplatin lomustine vincristine sul... adjuvant therap... iodine I 131 mo... radiation thera... | 3 Years - | Memorial Sloan Kettering Cancer Center | |
| Golden Halo, Static Magnetic and Electric Field Device, in Recurrent Glioblastoma | NCT05410301 | Glioblastoma Recurrent Gliob... | Static Magnetic... Lomustine Bevacizumab | 18 Years - | University of Iowa | |
| Testing the Addition of the Chemotherapy Drug Lomustine (Gleostine®) to the Usual Treatment (Temozolomide and Radiation Therapy) for Newly Diagnosed MGMT Methylated Glioblastoma | NCT05095376 | Glioblastoma Gliosarcoma | Lomustine Photon Beam Rad... Quality-of-Life... Questionnaire A... Temozolomide | 18 Years - 70 Years | NRG Oncology | |
| 6-TG, Capecitabine and Celecoxib Plus TMZ or CCNU for Anaplastic Glioma Patients | NCT00504660 | Anaplastic Glio... Glioblastoma Mu... Brain Cancer | Capecitabine Celecoxib (Cele... Temozolomide Lomustine 6-Thioguanine | 12 Years - | M.D. Anderson Cancer Center | |
| Radiation Therapy Plus Combination Chemotherapy in Treating Children With Medulloblastoma | NCT00053872 | Brain and Centr... | cisplatin lomustine vincristine sul... adjuvant therap... radiation thera... | 3 Years - 21 Years | National Cancer Institute (NCI) | |
| Study to Evaluate Safety, Tolerability, and Optimal Dose of Candidate GBM Vaccine VBI-1901 in Recurrent GBM Subjects | NCT03382977 | Glioblastoma Mu... | VBI-1901 Carmustine Lomustine | 18 Years - | VBI Vaccines Inc. | |
| A Study With L19TNF in Combination With Lomustine in Patients With Glioblastoma at Progression or Recurrence | NCT06336291 | Glioblastoma | L19TNF L19TNF L19TNF Lomustine Lomustine | 18 Years - | Philogen S.p.A. | |
| Combination Chemotherapy in Treating Patients With AIDS-Related Non-Hodgkin's Lymphoma | NCT00049439 | Lymphoma | filgrastim cyclophosphamid... etoposide lomustine procarbazine hy... | 16 Years - | Case Comprehensive Cancer Center | |
| Temozolomide, Thalidomide, and Lomustine (TTL) in Melanoma Patients | NCT00527657 | Brain Neoplasms Melanoma | Lomustine Temozolomide Thalidomide | 18 Years - | M.D. Anderson Cancer Center | |
| Standard Dose Bevacizumab Versus Low Dose Bevacizumab Plus Lomustine (CCNU) for Recurrent Glioblastoma Multiforme (GBM) | NCT01067469 | Brain Cancer Glioblastoma | Standard Dose B... Low Dose Bevaci... Lomustine | 18 Years - | M.D. Anderson Cancer Center | |
| Combination Chemotherapy and Bone Marrow Transplantation or Peripheral Stem Cell Transplantation in Treating Patients With Oligodendroglioma | NCT00003101 | Brain and Centr... | filgrastim busulfan lomustine procarbazine hy... thiotepa vincristine sul... autologous bone... peripheral bloo... | 18 Years - | Memorial Sloan Kettering Cancer Center | |
| A Comparison of Continuous Bevacizumab (Avastin) Treatment or Placebo in Addition to Lomustine Followed by Standard of Care After Disease Progression in Participants With Glioblastoma | NCT01860638 | Glioblastoma | Bevacizumab Lomustine Placebo Radiotherapy Temozolomide SOC Agent | 18 Years - | Hoffmann-La Roche | |
| Study to Evaluate Eflornithine + Lomustine vs Lomustine in Recurrent Anaplastic Astrocytoma (AA) Patients | NCT02796261 | Anaplastic Astr... Recurrent Anapl... | Eflornithine Lomustine Lomustine | 18 Years - | Orbus Therapeutics, Inc. | |
| Standard Dose Bevacizumab Versus Low Dose Bevacizumab Plus Lomustine (CCNU) for Recurrent Glioblastoma Multiforme (GBM) | NCT01067469 | Brain Cancer Glioblastoma | Standard Dose B... Low Dose Bevaci... Lomustine | 18 Years - | M.D. Anderson Cancer Center | |
| Phase I : Cediranib in Combination With Lomustine Chemotherapy in Recurrent Malignant Brain Tumour | NCT00503204 | Recurrent Gliob... Brain Tumor | Cediranib Lomustine | 18 Years - | AstraZeneca | |
| 9-ING-41 in Patients With Advanced Cancers | NCT03678883 | Cancer Pancreatic Canc... Sarcoma Renal Cancer Refractory Canc... Refractory Neop... Refractory Non-... Pancreatic Aden... Resistant Cance... Neoplasm Metast... Neoplasm of Bon... Neoplasm, Breas... Neoplasm of Lun... Neoplasms,Color... Neoplasms Pancr... Malignant Gliom... Malignancies Malignancies Mu... Bone Metastases Bone Neoplasm Bone Cancer Pancreas Cancer Pancreatic Neop... Breast Neoplasm... Acute T Cell Le... | 9-ING-41 Gemcitabine - 2... Doxorubicin. Lomustine Carboplatin. Nab paclitaxel. Paclitaxel. Gemcitabine - 2... Irinotecan | 18 Years - | Actuate Therapeutics Inc. | |
| Efficacy and Safety of AP 12009 in Patients With Recurrent or Refractory Anaplastic Astrocytoma or Secondary Glioblastoma | NCT00761280 | Anaplastic Astr... Glioblastoma | trabedersen temozolomide Drug delivery s... Placement of Dr... carmustine lomustine | 18 Years - 70 Years | Isarna Therapeutics GmbH | |
| Sonocloud-9 in Association With Carboplatin Versus Standard-of-Care Chemotherapies (CCNU or TMZ) in Recurrent GBM | NCT05902169 | Glioblastoma Recurrent Gliob... GBM | SonoCloud-9 (SC... Carboplatin Lomustine Temozolomide | 18 Years - | CarThera | |
| Phase I : Cediranib in Combination With Lomustine Chemotherapy in Recurrent Malignant Brain Tumour | NCT00503204 | Recurrent Gliob... Brain Tumor | Cediranib Lomustine | 18 Years - | AstraZeneca | |
| A Phase II/III Study of High-dose, Intermittent Sunitinib in Patients With Recurrent Glioblastoma Multiforme | NCT03025893 | Glioblastoma Mu... Glioblastoma, A... Glioblastoma Recurrent Brain... GBM | Sunitinib Lomustine | 18 Years - | Amsterdam UMC, location VUmc | |
| The RECSUR-study: Resection Versus Best Oncological Treatment for Recurrent Glioblastoma (ENCRAM 2302) | NCT06283927 | Glioblastoma Glioblastoma Mu... Glioblastoma, I... Glioblastoma Mu... Glioblastoma Mu... Recurrent Gliob... Astrocytoma, Ma... Astrocytoma of ... | Re-resection Temozolomide Lomustine Re-irradiation Experimental th... Best supportive... | 18 Years - 90 Years | Erasmus Medical Center | |
| Lomustine With and Without Reirradiation for First Progression of Glioblastoma: a Randomized Phase III Study | NCT05904119 | First Progressi... | Lomustine Reirradiation | 18 Years - | European Organisation for Research and Treatment of Cancer - EORTC | |
| Personalized Risk-Adapted Therapy in Post-Pubertal Patients With Newly-Diagnosed Medulloblastoma | NCT04402073 | Medulloblastoma | Sonidegib Cisplatin Lomustine Vincristine radiotherapy | 15 Years - | European Organisation for Research and Treatment of Cancer - EORTC | |
| Temozolomide Plus Lomustine Followed by Radiation Therapy in Treating Patients With High-Grade Malignant Glioma | NCT00006024 | Brain Tumor Central Nervous... | lomustine temozolomide | 3 Years - 21 Years | Children's Oncology Group | |
| Study of CCNU (Lomustine) Plus Dasatinib in Recurrent Glioblastoma (GBM) | NCT00948389 | Glioblastoma | Dasatinib Lomustine | 18 Years - | Bristol-Myers Squibb | |
| Lomustine in Treating Patients With Stage III or Stage IV Non-Small Cell Lung Cancer | NCT00293280 | Lung Cancer | lomustine | 18 Years - | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | |
| Laser Interstitial Thermal Therapy and Lomustine in Treating Patients With Recurrent Glioblastoma or Anaplastic Astrocytoma | NCT03022578 | IDH Family Wild... Recurrent Anapl... Recurrent Gliob... | Laser Interstit... Lomustine | 18 Years - | M.D. Anderson Cancer Center | |
| Combination Chemotherapy in Treating Patients With AIDS-Related Non-Hodgkin's Lymphoma | NCT00049439 | Lymphoma | filgrastim cyclophosphamid... etoposide lomustine procarbazine hy... | 16 Years - | Case Comprehensive Cancer Center | |
| Study to Evaluate Eflornithine + Lomustine vs Lomustine in Recurrent Anaplastic Astrocytoma (AA) Patients | NCT02796261 | Anaplastic Astr... Recurrent Anapl... | Eflornithine Lomustine Lomustine | 18 Years - | Orbus Therapeutics, Inc. | |
| Chemotherapy Followed by Radiation Therapy in Treating Adults With Supratentorial Glioma | NCT00002806 | Brain and Centr... | lomustine procarbazine hy... vincristine sul... low-LET photon ... | 18 Years - | Alliance for Clinical Trials in Oncology | |
| Methotrexate, Procarbazine, Lomustine, Dexamethasone, and Cytarabine in Treating Patients With Primary CNS Lymphoma | NCT00074191 | Lymphoma | cytarabine dexamethasone lomustine methotrexate procarbazine hy... | 16 Years - 75 Years | OHSU Knight Cancer Institute | |
| Phase II Trial of Romiplostim for Thrombocytopenia Induced by Lomustine at First Progression of MGMT Promoter-meth Glioblastoma | NCT04933942 | First Progressi... | Lomustine Romiplostim | 18 Years - | European Organisation for Research and Treatment of Cancer - EORTC | |
| Oral Combination Chemotherapy in Treating Elderly Patients With Intermediate or High-Grade Non-Hodgkin's Lymphomas | NCT00003113 | Lymphoma | filgrastim cyclophosphamid... etoposide lomustine procarbazine hy... radiation thera... | 60 Years - | Case Comprehensive Cancer Center | |
| Monitoring Anti-angiogenic Therapy in Brain Tumors by Advanced MRI | NCT02843230 | Glioblastoma | Avastin Lomustine Temozolomide MRI MRS DSC | 18 Years - | Massachusetts General Hospital | |
| Radiation Therapy Plus Combination Chemotherapy in Treating Children With Medulloblastoma | NCT00002875 | Brain Tumors Central Nervous... | filgrastim cisplatin cyclophosphamid... lomustine mesna vincristine sul... low-LET electro... low-LET photon ... | 3 Years - 22 Years | Children's Oncology Group | |
| A Study of Treatment for Medulloblastoma Using Sodium Thiosulfate to Reduce Hearing Loss | NCT05382338 | Medulloblastoma | Cisplatin Cyclophosphamid... Lomustine Mesna Quality-of-Life... Radiation Thera... Sodium Thiosulf... Survey Administ... Vincristine | 3 Years - 21 Years | Children's Oncology Group | |
| Study of CCNU (Lomustine) Plus Dasatinib in Recurrent Glioblastoma (GBM) | NCT00948389 | Glioblastoma | Dasatinib Lomustine | 18 Years - | Bristol-Myers Squibb |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
